Total Payments
$94,161
2024 Payments
$22,712
Companies
49
Transactions
418
Medicare Patients
10,898
Medicare Billing
$1.5M
Payment Breakdown by Category
Consulting$59,135 (62.8%)
Food & Beverage$13,923 (14.8%)
Travel$9,572 (10.2%)
Other$6,390 (6.8%)
Education$4,875 (5.2%)
Gifts$200.12 (0.2%)
Research$66.12 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $59,135 | 28 | 62.8% |
| Food and Beverage | $13,923 | 334 | 14.8% |
| Travel and Lodging | $9,572 | 30 | 10.2% |
| Education | $4,875 | 20 | 5.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $4,500 | 3 | 4.8% |
| Honoraria | $1,890 | 1 | 2.0% |
| Gift | $200.12 | 1 | 0.2% |
| Unspecified | $66.12 | 1 | 0.1% |
Payments by Type
General
$94,095
417 transactions
Research
$66.12
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AngioDynamics, Inc. | $62,720 | 74 | $0 (2024) |
| INTUITIVE SURGICAL, INC. | $6,518 | 37 | $0 (2024) |
| Ethicon Inc. | $5,300 | 12 | $0 (2024) |
| ABBVIE INC. | $4,887 | 19 | $0 (2024) |
| KARL STORZ Endoscopy-America | $4,309 | 8 | $0 (2023) |
| PFIZER INC. | $2,588 | 46 | $0 (2024) |
| Astellas Pharma US Inc | $1,558 | 43 | $0 (2024) |
| Axonics, Inc. | $664.18 | 12 | $0 (2024) |
| Olympus America Inc. | $429.22 | 10 | $0 (2024) |
| Janssen Biotech, Inc. | $403.38 | 21 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $22,712 | 123 | AngioDynamics, Inc. ($10,550) |
| 2023 | $35,897 | 109 | AngioDynamics, Inc. ($29,888) |
| 2022 | $26,175 | 72 | AngioDynamics, Inc. ($22,071) |
| 2021 | $4,106 | 22 | AbbVie Inc. ($3,044) |
| 2020 | $2,334 | 25 | AbbVie Inc. ($1,523) |
| 2019 | $1,423 | 41 | Intuitive Surgical, Inc. ($597.15) |
| 2018 | $184.76 | 8 | E.R. Squibb & Sons, L.L.C. ($66.12) |
| 2017 | $1,330 | 18 | Intuitive Surgical, Inc. ($1,029) |
All Payment Transactions
418 individual payment records from CMS Open Payments — Page 1 of 17
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | AngioDynamics, Inc. | NANOKNIFE (Device) | Consulting Fee | Cash or cash equivalent | $2,800.00 | General |
| Category: OS | ||||||
| 12/19/2024 | Teleflex LLC | — | Food and Beverage | In-kind items and services | $19.21 | General |
| 12/18/2024 | Ferring Pharmaceuticals Inc. | ADSTILADRIN (Biological) | Food and Beverage | In-kind items and services | $13.27 | General |
| Category: ONCOLOGY | ||||||
| 12/17/2024 | ABBVIE INC. | LUPRON DEPOT (Drug) | Food and Beverage | In-kind items and services | $21.34 | General |
| Category: ENDOCRINOLOGY | ||||||
| 12/12/2024 | Ferring Pharmaceuticals Inc. | ADSTILADRIN (Biological) | Food and Beverage | In-kind items and services | $20.83 | General |
| Category: ONCOLOGY | ||||||
| 12/12/2024 | Endo USA, Inc. | XIAFLEX (Biological) | Food and Beverage | In-kind items and services | $13.37 | General |
| Category: UROLOGY | ||||||
| 12/06/2024 | Ethicon Inc. | — | Consulting Fee | Cash or cash equivalent | $550.00 | General |
| 12/05/2024 | UROGEN PHARMA, INC. | JELMYTO (Drug) | Food and Beverage | In-kind items and services | $140.07 | General |
| Category: UROTHELIAL CANCER | ||||||
| 12/05/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug), Xofigo | Food and Beverage | In-kind items and services | $19.86 | General |
| Category: Oncology | ||||||
| 12/03/2024 | LANTHEUS MEDICAL IMAGING, INC. | — | Food and Beverage | In-kind items and services | $18.07 | General |
| 11/21/2024 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $25.39 | General |
| Category: Oncology | ||||||
| 11/21/2024 | Ferring Pharmaceuticals Inc. | ADSTILADRIN (Biological) | Food and Beverage | In-kind items and services | $19.76 | General |
| Category: ONCOLOGY | ||||||
| 11/19/2024 | UROGEN PHARMA, INC. | JELMYTO (Drug) | Food and Beverage | In-kind items and services | $19.03 | General |
| Category: UROTHELIAL CANCER | ||||||
| 11/18/2024 | AngioDynamics, Inc. | NANOKNIFE (Device) | Food and Beverage | In-kind items and services | $18.50 | General |
| Category: OS | ||||||
| 11/18/2024 | AngioDynamics, Inc. | NANOKNIFE (Device) | Food and Beverage | In-kind items and services | $11.88 | General |
| Category: OS | ||||||
| 11/17/2024 | AngioDynamics, Inc. | NANOKNIFE (Device) | Food and Beverage | In-kind items and services | $7.11 | General |
| Category: OS | ||||||
| 11/15/2024 | ABBVIE INC. | LUPRON DEPOT (Drug) | Food and Beverage | In-kind items and services | $15.70 | General |
| Category: ENDOCRINOLOGY | ||||||
| 11/12/2024 | Ethicon Inc. | — | Consulting Fee | Cash or cash equivalent | $100.00 | General |
| 11/07/2024 | Astellas Pharma US Inc | Padcev (Drug) | Food and Beverage | In-kind items and services | $25.46 | General |
| Category: Oncology | ||||||
| 10/31/2024 | Ferring Pharmaceuticals Inc. | ADSTILADRIN (Biological) | Food and Beverage | In-kind items and services | $20.83 | General |
| Category: ONCOLOGY | ||||||
| 10/31/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug), Xofigo | Food and Beverage | In-kind items and services | $13.15 | General |
| Category: Oncology | ||||||
| 10/31/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug), Xofigo | Food and Beverage | In-kind items and services | $2.04 | General |
| Category: Oncology | ||||||
| 10/24/2024 | ABBVIE INC. | LUPRON DEPOT (Drug) | Food and Beverage | In-kind items and services | $24.46 | General |
| Category: ENDOCRINOLOGY | ||||||
| 10/22/2024 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $25.40 | General |
| Category: Oncology | ||||||
| 10/18/2024 | Boston Scientific Corporation | SpaceOAR VUE System - 10mL (Device) | Food and Beverage | In-kind items and services | $41.80 | General |
| Category: SpaceOAR VUE_URO | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Safety and Tolerability of TAR 200 and Nivolumab in Subjects With Muscle Invasive Bladder Cancer | E.R. Squibb & Sons, L.L.C. | $66.12 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 29 | 2,486 | 7,528 | $1.6M | $331,417 |
| 2022 | 34 | 2,523 | 9,171 | $1.6M | $365,631 |
| 2021 | 36 | 2,815 | 11,769 | $1.7M | $389,155 |
| 2020 | 40 | 3,074 | 14,013 | $1.7M | $374,118 |
Total Patients
10,898
Total Services
42,481
Medicare Billing
$1.5M
Procedure Codes
139
All Medicare Procedures & Services
139 procedure records from CMS Medicare Utilization — Page 1 of 6
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 12 | 3,780 | $102,060 | $69,770 | 68.4% |
| 55874 | Injection of biodegradable material next to prostate | Office | 2023 | 27 | 27 | $202,257 | $64,040 | 31.7% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2023 | 44 | 399 | $800,967 | $53,709 | 6.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 368 | 491 | $112,439 | $46,732 | 41.6% |
| 52000 | Diagnostic exam of bladder and urethra using an endoscope | Office | 2023 | 85 | 106 | $87,132 | $20,486 | 23.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 209 | 233 | $36,581 | $15,193 | 41.5% |
| 84153 | Psa (prostate specific antigen) measurement, total | Office | 2023 | 336 | 572 | $53,768 | $10,307 | 19.2% |
| 55700 | Biopsy of prostate gland | Office | 2023 | 47 | 47 | $27,636 | $8,970 | 32.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 57 | 57 | $20,463 | $7,266 | 35.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 43 | 45 | $13,815 | $6,650 | 48.1% |
| 76872 | Ultrasound scan of pelvic region through rectum | Office | 2023 | 58 | 58 | $22,753 | $6,636 | 29.2% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 344 | 539 | $10,780 | $4,520 | 41.9% |
| 51798 | Ultrasound measurement of bladder capacity after voiding | Office | 2023 | 175 | 214 | $12,626 | $1,854 | 14.7% |
| 96402 | Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 45 | 69 | $6,555 | $1,812 | 27.7% |
| 99221 | Initial hospital care with straightforward or low level of medical decision making, per day, if using time, at least 40 minutes | Facility | 2023 | 25 | 25 | $5,475 | $1,729 | 31.6% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 18 | 24 | $3,624 | $1,562 | 43.1% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 18 | 18 | $4,230 | $1,495 | 35.3% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 18 | 20 | $3,580 | $1,423 | 39.7% |
| 84403 | Testosterone (hormone) level, total | Office | 2023 | 35 | 45 | $5,985 | $1,138 | 19.0% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 28 | 30 | $2,820 | $1,080 | 38.3% |
| 81003 | Automated urinalysis test | Office | 2023 | 290 | 437 | $5,244 | $959.44 | 18.3% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 19 | 80 | $4,960 | $875.98 | 17.7% |
| 51700 | Simple bladder irrigation and/or instillation | Office | 2023 | 13 | 14 | $3,136 | $866.21 | 27.6% |
| 99441 | Telephone medical discussion with physician, 5-10 minutes | Office | 2023 | 24 | 25 | $4,475 | $812.86 | 18.2% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 11 | 15 | $1,245 | $576.66 | 46.3% |
About Dr. Amit Patel, MD
Dr. Amit Patel, MD is a Urology healthcare provider based in Hinsdale, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/24/2008. The National Provider Identifier (NPI) number assigned to this provider is 1437324084.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Amit Patel, MD has received a total of $94,161 in payments from pharmaceutical and medical device companies, with $22,712 received in 2024. These payments were reported across 418 transactions from 49 companies. The most common payment nature is "Consulting Fee" ($59,135).
As a Medicare-enrolled provider, Patel has provided services to 10,898 Medicare beneficiaries, totaling 42,481 services with total Medicare billing of $1.5M. Data is available for 4 years (2020–2023), covering 139 distinct procedure/service records.
Ad
Practice Information
- Specialty Urology
- Location Hinsdale, IL
- Active Since 04/24/2008
- Last Updated 08/17/2023
- Taxonomy Code 208800000X
- Entity Type Individual
- NPI Number 1437324084
Products in Payments
- NANOKNIFE (Device) $62,510
- Da Vinci Surgical System (Device) $6,518
- LUPRON DEPOT (Drug) $4,867
- n.a. (Device) $3,960
- TALZENNA (Drug) $1,890
- XTANDI (Drug) $653.63
- ORGOVYX (Drug) $602.54
- Bulkamid (Device) $521.75
- Xtandi (Drug) $448.27
- ERLEADA (Drug) $425.35
- iTIND System (Device) $412.07
- Nubeqa (Drug) $252.89
- JELMYTO (Drug) $211.96
- NanoKnife (Device) $210.63
- GEMTESA (Drug) $179.21
- ADSTILADRIN (Biological) $178.13
- MYRBETRIQ (Drug) $165.28
- XARELTO (Drug) $162.03
- Myrbetriq (Drug) $152.76
- SpaceOAR VUE System - 10mL (Device) $147.71
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.